153 related articles for article (PubMed ID: 1680550)
1. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity.
Mickisch GH; Licht T; Merlino GT; Gottesman MM; Pastan I
Cancer Res; 1991 Oct; 51(19):5417-24. PubMed ID: 1680550
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.
Mickisch GH; Pai LH; Gottesman MM; Pastan I
Cancer Res; 1992 Aug; 52(16):4427-32. PubMed ID: 1353705
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance.
Mickisch GH; Merlino GT; Galski H; Gottesman MM; Pastan I
Proc Natl Acad Sci U S A; 1991 Jan; 88(2):547-51. PubMed ID: 1671173
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistant transgenic mice as a novel pharmacologic tool.
Mickisch GH; Pastan I; Gottesman MM
Bioessays; 1991 Aug; 13(8):381-7. PubMed ID: 1683231
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
Hanania EG; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
[TBL] [Abstract][Full Text] [Related]
8. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter.
Lelong IH; Guzikowski AP; Haugland RP; Pastan I; Gottesman MM; Willingham MC
Mol Pharmacol; 1991 Oct; 40(4):490-4. PubMed ID: 1681415
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets in oncology: implications of the multidrug resistance gene.
Lum BL; Gosland MP; Kaubisch S; Sikic BI
Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and bone marrow protection of the mdr1 gene and over-dose chemotherapy with doxorubicin for rabbits with VX2 hepatocarcinoma.
Wang Y; Jin XQ; Wang S; Wang Q; Luo Q; Luo XJ
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):545-51. PubMed ID: 17085340
[TBL] [Abstract][Full Text] [Related]
11. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I
J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
13. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
14. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
15. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.
Willingham MC; Cornwell MM; Cardarelli CO; Gottesman MM; Pastan I
Cancer Res; 1986 Nov; 46(11):5941-6. PubMed ID: 3756931
[TBL] [Abstract][Full Text] [Related]
16. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
17. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
18. Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
Suzuki M; Sugimoto Y; Tsukahara S; Okochi E; Gottesman MM; Tsuruo T
Clin Cancer Res; 1997 Jun; 3(6):947-54. PubMed ID: 9815770
[TBL] [Abstract][Full Text] [Related]
19. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P
Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
